<< Back To Search

A Study to Evaluate CC-92480, Bortezomib and Dexamethasone (480Vd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)

Notify the Multiple Myeloma Research Foundation You Are Interested In This Trial

Summary

Third Opinion Trial Synopsis:
This study is testing two different treatments for people with a type of cancer called multiple myeloma. The study is comparing the effectiveness and safety of one treatment called 480Vd to another treatment called PVd. Both treatments include medicines called bortezomib and dexamethasone, but 480Vd also includes a medicine called CC-92480. The study is for people who have already tried 1 to 3 other treatments and have taken a medicine called lenalidomide before.
*Third Opinion AI Generated Synopsis

Trial Summary
The purpose of this study is to compare the efficacy and safety of CC-92480, bortezomib and dexamethasone (480Vd) versus pomalidomide, bortezomib and dexamethasone (PVd) in participants with relapsed or refractory multiple myeloma (RRMM) who received between 1 to 3 prior lines of therapy and who have had prior lenalidomide exposure.

Locations & Contact

Fill out the form and "Notify Multiple Myeloma Research Foundation" to let the Multiple Myeloma Research Foundation know you are interested in this trial.

Please share any additional considerations or concerns:
Example: Are you newly diagnosed? What treatments have you already been on?

Contacts: